14 between the whole group of schizophrenic patients and controls. By contrast, an excess of the 172-176 bp alleles was found in patients with late onset, in neurolepticresponding patients and in non-substance-abusing patients. BDNF gene variants thus appear to be associated with developmental features of schizophrenia. In addition, this association with good treatment responding was independent from the association found with the DRD3 BalI gene polymorphism in the same population. 15 These results suggest an independent contribution of each gene to a treatment-sensitive form of schizophrenia. Molecular Psychiatry (2000) 5, 558-562.
Eighty-eight unrelated in-or out-patients with schizophrenia or schizo-affective disorder (DSM-III-R criteria) and fifty-two unrelated age-and gender-matched controls with no personal and/or familial history of psychiatric disease or substance abuse were recruited from a French Caucasian population.
The genotype distribution did not show a departure from Hardy-Weinberg equilibrium in either controls (chi 2 = 2.90; df = 9; P = 0.97) or patients (chi 2 = 7.10; df = 9; P = 0.63). The allelic distribution (Table 1) was similar to that reported 16 in patients (chi 2 = 1.18, P = 0.99, df = 4) and in controls (chi 2 = 6.29, df = 4, P = 0.18). A new allele with one more GT repeat (176 bp) was found. In a Japanese population, an insertion of nucleotides adjacent to the dinucleotide polymorphic site was found in four subjects. 17 Alleles with lesser repeats (164 bp and 154 bp) have also been reported. 16 As in previous reports, 16, 17 we did not find significant differences in BDNF gene allele (WI = 9960; P = 0.14) or genotype distribution (chi 2 = 5.81; df = 9; P = 0.75) between the group of schizophrenic patients as a whole and controls, but a false negative result can not be ruled out, due to the limited size of the sample. Negative results were also found in a larger sample (234 controls, 220 patients), 16 in which, unfortunately, no additional clinical features were taken into account.
Since schizophrenia is a disease with heterogeneous clinical expression and BDNF is a critical factor in neurodevelopment, in particular of the mesolimbic DA system, we analyzed allelic distribution according to additional clinical features, ie age at onset, therapeutic response to antipsychotic drugs and substance abuse.
Schizophrenic patients with an age at first contact with a practitioner for psychiatric reason later than 25 years old (n = 20) had a significantly different allelic distribution compared with either patients with first contact at 25 years or below (WI = 3311, P = 0.007) or controls (WI = 1553, P = 0.005). For statistical analysis purposes, alleles were grouped in 'short' (166-170 bp) and 'long' (172-176 bp) alleles. Patients with late onset had an excess of long alleles as compared to patients with an age at onset before 25 years (chi 2 = 5, P = 0.03, odds ratio (OR) = 2.3). Accordingly, patients with the 'long' alleles had an age at onset significantly higher than the remaining patients (23.92 ± 5 vs 19.34 ± 7 years old, WI = 641.0, P = 0.024).
Allele distribution significantly differed in patients who at least partly responded to neuroleptic treatment ('treatment-responding') as compared to patients with no clinical remission ('refractory' patients, n = 20; WI = 2106; P = 0.01) and controls (WI = 8061; P = 0.03). Treatment-responding patients had an excess of long alleles (172-176 bp) as compared to refractory schizophrenic patients (chi 2 = 4.6, P = 0.04, OR = 2.7). In contrast with previous studies, in our sample, age at onset in treatment-responding patients was not significantly different from that of refractory patients (20.4 ± 7 vs 18.5 ± 7, WI = 757, P = 0.43) and treatment responding patients were equally distributed among patients with age at onset before or after 25 years old (Yates corrected chi 2 = 0.23). In fact, in the literature, treatment-sensitive 'late onset' schizophrenia refers to a particular form of schizophrenia with first prodromal or acute psychotic symptoms later than 40-45 years, 18 that was not present in our sample. In the absence of interaction between treatment response and age at onset in our sample, the difference in allelic distribution seen with regard to treatment response can be attributed to an association with treatment responsiveness itself. Patients with combined feature of treatment response and late onset (n = 36) had an excess of the long alleles (172-176 bp) as compared to the remaining patients (P = 0.007, OR = 2.94). This is consistent with the known involvement of BDNF in the development of the DA systems. It should be interesting to further study samples including very late-onset schizophrenia (ie first symptoms later than 45 years old).
Allele distribution in 'non substance abusing' patients significantly differed from that in controls (WI = 6299; P = 0.03) and tended to differ from that in patients who had at least once abused or were dependent on any kind of psychoactive substance ('substance abusing patients', n = 36; WI = 4221; P = 0.07). As a tendency, non substance-abusing patients had an excess of the long alleles (172-176 bp) as compared to controls (chi 2 = 3.7, P = 0.06). This was not due to an unequal distribution of substance-abusing patients in treatment-responding or refractory subgroups (chi 2 = 0.25, P = 0.62) or in subgroups defined by age at onset before or later than 25 years (chi 2 = 1.03, P = 0.44). In addition, age at onset was not significantly different in non-substance-abusing compared to substance-abusing patients (20.4 ± 7 vs 19.3 ± 7 years of age, WI = 989, P = 0.6). This suggests that the BDNF gene variants could influence the phenotypic expression of schizophrenia in relation to predisposition to substance abuse. It is not clear whether this is specific to schizophrenia and it should be further documented in a sample of drug addicts. Interestingly, BDNF is up-regulated during chronic opiate treatment and withdrawal in rats. 19 
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Using the same clinical characteristics in the same population of patients with schizophrenia, we previously reported that homozygosity at the DRD3 BalI polymorphism was associated with substance abuse and responsiveness to neuroleptics. There was no statistical difference with regards to age at onset of schizophrenia (unpublished results). In that case, the combined features of substance abuse and responsiveness to treatment were associated with homozygosity for the DRD3 BalI polymorphism. We thus tested whether there was an interaction of DRD3 and BDNF (long vs short) gene variants in this association.
DRD3 heterozygote (1-2) and homozygote (2-2 or 1-1) genotypes were equally distributed between the BDNF genotypes with at least one long allele (172-176 bp) vs those with two short alleles, indicating that the association found here with good therapeutic response was not a false positive effect due to a bychance stratification in DRD3 homozygosity distribution (chi 2 = 0.001, P = 0.98, OR = 1.01). The logistic regression including the effect of the BDNF and DRD3 gene variants and a possible interaction effect of the two showed no significant interaction between the two genes (Wald test = 0.25; P = 0.62). This interaction term was thus dropped in the subsequent analysis. The effect of the DRD3 gene was then significant (adjusted OR = 3.5; Wald test = 4.85, P = 0.028) and the effect of the BDNF gene was almost significant (adjusted OR = 3.0; Wald test = 3.42; P = 0.06). These results indicate that each of the two polymorphisms contributes separately to the therapeutic response.
BDNF and DRD3 gene variants appear thus to be associated with distinct schizophrenic phenotypes, of developmental and pharmacological nature respectively. Namely, the associations of the BalI polymorphism DRD3 gene variants with tardive dyskinesia 20, 21 and with treatment response 15 in schizophrenic patients, suggest that DRD3 gene variants influence the pharmacological sensitivity to antipsychotic drugs. On the other hand, excess of the BDNF gene 'long' alleles is found in patients with age at onset later than 25 years and treatment responsiveness, clinical features that are associated with a 'less developmentally weighted' form of schizophrenia. Such an association might be found in other psychiatric diseases in which neurodevelopmental factors have been suggested. Our observation of an excess of the long alleles in non substance-abusing patients is consistent with the involvement of BDNF in the development of the DA mesolimbic 'reward' system, involved in drug abuse and dependence. The functional significance of the BDNF gene polymorphism is unclear. Since it is located 1040 bp upstream of the transcription initiation site, an effect on the regulatory components of this gene cannot be excluded but remains to be demonstrated.
The analysis of the respective effect of DRD3 BalI polymorphism and BDNF alleles indicates that each of these genetic markers is independently associated with therapeutic response in schizophrenia. Since BDNF presumably controls DRD3 gene expression, 13 it is conceivable that alterations in the function of each gene independently contribute to a DRD3 over-expression, which was found in post-mortem brain of patients with schizophrenia. 22 The association of variants of each of these genes with the therapeutic response in schizophrenia is indeed consistent with the fact that antipsychotic drugs act at the DRD3, 23 and may therefore normalize the transmission through this receptor in the subset of treatment-sensitive patients. This would be the first example of independent effects of two functionally interacting genes in schizophrenia, in agreement with the presumed polygenic inheritance of the susceptibility to this disorder, each gene having a small contribution.
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Materials and methods
Subjects and psychiatric assessment
Eighty-eight unrelated patients (55 males; 33 females; mean age: 33.3 ± 9.1 years old) with schizophrenia (n = 84) or schizoaffective disorder (n = 4) were examined by a trained psychiatrist with a semi-standardized interview (SADS-LA lifetime version anxiety versionrevised, 25 French translation) leading to lifetime diagnosis according to DSM-III-R criteria. 26 In addition, information on clinical and treatment history was obtained from the medical staff of our hospital or from previous hospitalizations (most of the patients have been treated in our department from the beginning of their disease or less than 2 years after the onset of the disease), ambulatory private psychiatrists, review of case notes and, whenever possible, information from the family. The majority of patients (77%) had a positive familial history of psychiatric disease (second degree), with 50 patients (57%) having a familial history of psychosis (first or second degree). Psychiatric assessment also included evaluation of the course of illness (mean duration of the disease ± SD = 13.3 ± 10 years), current symptomatology with Positive and Negative Syndrome Scale 27 (PANSS mean total score: 80.8 ± 18).
The age at first contact with medical practitioner for psychological or psychiatric reason was used as age at onset (mean ± SD: 20.0 ± 6.9 years old). Late or early onset of schizophrenia was defined on the basis of a first contact before or after the age of 25. This cut-off of 25 was chosen because, in most cases, the first symptoms (whether specific or not) occur at or before the age of 25. 28 It fitted approximately to the mean + one SD of our sample. Patients with an age at onset before or at the age of 25 years corresponded to 77% of the studied population (n = 68). The same cut-off was chosen in male and female, since the mean age at onset was similar in both genders in our population in agreement of previous reports on the familial form of schizophrenia. 18, 29 Response to neuroleptic treatment was evaluated on the basis of the rapidity and quality of symptom remission, necessity for prolonged hospitalization, ability for autonomy and social rehabilitation. 30 'Treatment-responding' patients (n = 68, score: 1-4) had at least a partial clinical remission under antipsychotic treatment allowing discharge from hospital. Conversely, 'treatment refractory' patients (n = 20, score: 5-6) had no clinical remission despite several trials with different antipsychotic drugs for a sufficient duration and required permanent day care.
Former or current substance abuse of and/or dependence on any kind of psychoactive substance including alcohol or tranquilizers, but not nicotine, were systematically screened. Patients who had at least once in their life fulfilled the DSM-III-R criteria for abuse or dependence (but not occasional use) were defined as 'substance-abusing' (n = 36). 'Non substance-abusing' schizophrenic patients (n = 52) had never, in all their life, fulfilled the DSM-IIIR criteria for abuse and/or dependence on any kind of psychoactive substance. In every case, substance-induced psychosis could be eliminated: in only four patients, the interview found that substance abuse preceded psychotic or prodromal symptoms, but psychotic symptoms remained much more than 6 weeks after the end of intoxication and the abuse was of moderate extent and/or limited duration.
The fifty-two unrelated controls (26 males, 26 females) were locally recruited (medical and non medical staff of the hospital, medical students) and screened with a semi-standardized interview (SCID-NP) and additional questions about family history (first and second degree relatives), done by a psychologist independent of the study. They were included only when they had no personal and/or familial psychiatric or substance abuse history. Patients did not differ significantly from controls with regard to gender distribution (P = 0.17) or ages (35.8 ± 10 years old in controls, P = 0.36).
All subjects but four (two patients and two controls) had at least three French Caucasian grandparents (with the possibility of one grandparent originating from another country of Western Europe, except two patients with one grand-parent of Caribbean origin). The results were unchanged when excluding those six subjects. The psychiatric assessment was completed before genetic analysis and the choice for analysis fac-tors was done blind to the genotyping results. This study received the agreement of the local Ethical Committee. All subjects gave their written informed consent prior to the study.
DNA analysis
Venous blood samples were collected in ethylenediaminetetracetic acid-containing tubes. Genomic DNA was extracted from peripheral leukocytes of venous blood samples, collected in EDTA-containing tubes. After amplification by PCR with primers flanking exon 1 (5Ј-GCC-ACT-TTA-TCT-CCT-CCA-GT-3Ј; 5Ј AGC-ACT-AGC-TGC-CTA-TTC-CA-3Ј) 14 and thermostable Taq Polymerase (AmpliTaq, Perkin Elmer Cetus, Rockville, MD, USA), products were resolved on 6% DNA sequencing gels and visualized by autoradiography. Genotyping was carried out blind to the clinical status and was at least duplicated.
Statistical analysis
Genotype distribution was compared to the predictable value from Hardy-Weinberg equilibrium. Chi-Square was used for categorical comparisons. Allele distribution was analyzed with the non-parametric MannWhitney test. Corrections for multiple testing (Bonferroni) were not applied because analyses were of exploratory nature. Since the 172-bp, 174-bp and 176-bp alleles varied in the same direction, as compared to 166-bp, 168-bp and 170-bp alleles, alleles were classified in two groups, referred to as 'long' and 'short' alleles, respectively. The hypothesis of association between clinical variables and long alleles (172-176 bp) was tested with Pearson chi-square or, when appropriate, Yates corrected chi-square. The non-parametric Mann-Whitney U test was used to compare the distribution of allele sizes in sub-groups of patients and controls.
Logistic regression was used to describe the loglinear relationship between the genotypes for BDNF and DRD3 genes and therapeutic response. First, the full model with interaction between BDNF and DRD3 genes was tested. Because the interaction was not significant, the term corresponding to the interaction was dropped. The Wald test was used to test the significance of the coefficient of each component included in the model.
